Stem cell therapy biotech PrimeGen US is taking the less-traveled special purpose acquisition company (SPAC) route to the ...

Feb 4 (Reuters) - Biotech firm PrimeGen US will go public in the United States through a $1.5 billion deal with blank-check ...

The offering is one of four biotech IPOs that could price by Friday, and comes during the busiest week for such activity ...

The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...

In a stock market currently obsessed with interest rate cuts and the artificial intelligence (AI) boom, it is easy to ...

This board strengthens Serpin Pharma’s ability to advance innovative immune‑modulating therapeutics and expand our ...

A major biotech company has announced plans to lay off more than 100 positions from its Franklin, Massachusetts, facility. According to a Workers Adjustment and Retraining Notification notice, layoffs ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

A large biotech fund that's an insider at Cogent Biosciences recently sold millions of shares amid the company's best annual ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

Feb 4 (Reuters) - Biotech firm Bio-Techne beat analysts' estimates for second-quarter revenue and profit on Wednesday, helped by robust demand for its products used in drug development. The ...

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.